Prudential Financial Inc. Has $1.35 Million Holdings in STAAR Surgical (NASDAQ:STAA)

Prudential Financial Inc. trimmed its holdings in STAAR Surgical (NASDAQ:STAA) by 1.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 50,570 shares of the medical instruments supplier’s stock after selling 980 shares during the quarter. Prudential Financial Inc. owned 0.10% of STAAR Surgical worth $1,348,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Quarry LP acquired a new position in STAAR Surgical during the 3rd quarter valued at $50,000. Illinois Municipal Retirement Fund lifted its stake in shares of STAAR Surgical by 8.3% in the fourth quarter. Illinois Municipal Retirement Fund now owns 30,144 shares of the medical instruments supplier’s stock valued at $732,000 after buying an additional 2,318 shares during the period. FMR LLC grew its position in STAAR Surgical by 79.3% during the third quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier’s stock worth $263,000 after buying an additional 3,136 shares in the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych raised its holdings in STAAR Surgical by 9.7% in the 4th quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 39,500 shares of the medical instruments supplier’s stock valued at $959,000 after acquiring an additional 3,500 shares in the last quarter. Finally, HighTower Advisors LLC raised its holdings in STAAR Surgical by 42.6% in the 4th quarter. HighTower Advisors LLC now owns 12,956 shares of the medical instruments supplier’s stock valued at $315,000 after acquiring an additional 3,871 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

Insider Transactions at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. acquired 8,221 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The stock was acquired at an average price of $21.50 per share, for a total transaction of $176,751.50. Following the completion of the acquisition, the insider now owns 10,878,007 shares of the company’s stock, valued at $233,877,150.50. This trade represents a 0.08 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders acquired a total of 1,128,072 shares of company stock worth $18,842,293 in the last quarter. 1.00% of the stock is owned by company insiders.

STAAR Surgical Trading Down 8.5 %

Shares of STAA stock opened at $15.92 on Friday. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $52.68. The firm’s 50 day moving average is $18.82 and its 200-day moving average is $24.71. The firm has a market capitalization of $785.25 million, a price-to-earnings ratio of -38.83 and a beta of 0.75.

Analyst Ratings Changes

Several brokerages have recently weighed in on STAA. Piper Sandler decreased their target price on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 12th. Canaccord Genuity Group lowered their price objective on STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a research note on Thursday, February 13th. BTIG Research downgraded STAAR Surgical from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 12th. StockNews.com cut STAAR Surgical from a “hold” rating to a “sell” rating in a research report on Thursday, February 13th. Finally, Jefferies Financial Group cut shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $25.29.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.